AB Science Identifies Plasma Biomarker for Masitinib’s ALS Treatment
Event summary
- AB Science identified a plasma biomarker indicating masitinib’s activity in treating ALS, targeting proinflammatory microglia.
- The biomarker is also applicable to progressive multiple sclerosis and Alzheimer’s disease.
- The biomarker could help determine patient response to treatment, potentially aiding regulatory approval.
- The biomarker will be introduced in phase 3 trials for ALS, progressive MS, and Alzheimer’s disease.
- The biomarker remains undisclosed for patent protection.
The big picture
AB Science’s discovery of a plasma biomarker for masitinib’s activity in ALS marks a strategic shift in targeting neurodegenerative diseases. The biomarker’s potential to identify responsive patients could streamline clinical trials and regulatory approvals, addressing a critical unmet need in ALS treatment. This development aligns with broader industry trends toward precision medicine and biomarker-driven drug development, particularly in complex diseases with heterogeneous patient responses.
What we're watching
- Clinical Validation
- Whether the biomarker’s integration into phase 3 trials will validate masitinib’s mechanism of action in humans.
- Regulatory Pathway
- How the biomarker could facilitate FDA approval by serving as a surrogate endpoint for ALS treatment.
- Market Expansion
- The pace at which AB Science can apply this biomarker to other neurodegenerative diseases like MS and Alzheimer’s.
Our editorial coverage: